Recommended Reading on Cardiovascular Pharmacotherapy

ESC Working Group on Cardiovascular Pharmacotherapy

2025 ESC Guidelines for the management of myocarditis and pericarditis Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC)<br />Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS)

European Heart Journal

Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing &amp; Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy

European Heart Journal

Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis

European Heart Journal - Cardiovascular Pharmacotherapy

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024

European Heart Journal - Cardiovascular Pharmacotherapy

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy A clinical consensus statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care (ACVC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy and the European Association for Haemophilia and Allied Disorders (EAHAD)

European Heart Journal - Cardiovascular Pharmacotherapy

Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals

European Heart Journal - Cardiovascular Pharmacotherapy

Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI

European Heart Journal - Cardiovascular Pharmacotherapy

Management of dyslipidaemia in patients with comorbidities—facing the challenge Value and limitations of lipid-lowering drugs in liver disease Effects/Interactions of lipid-lowering agents on/with the liver

European Heart Journal - Cardiovascular Pharmacotherapy

Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation

European Heart Journal - Cardiovascular Pharmacotherapy

The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease

European Heart Journal

Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

European Heart Journal

Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

European Heart Journal - Cardiovascular Pharmacotherapy

Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis

European Heart Journal

Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

European Heart Journal

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

European Heart Journal - Cardiovascular Pharmacotherapy

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

European Heart Journal - Cardiovascular Pharmacotherapy

The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease

European Heart Journal

Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of &gt;20 000 patients

European Heart Journal - Cardiovascular Pharmacotherapy

Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy

β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction

European Heart Journal - Cardiovascular Pharmacotherapy

Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients

European Heart Journal - Cardiovascular Pharmacotherapy

Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

European Heart Journal - Cardiovascular Pharmacotherapy

Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters

European Heart Journal - Cardiovascular Pharmacotherapy

Medication in adults after atrial switch for transposition of the great arteries: clinical practice and recommendations

European Heart Journal - Cardiovascular Pharmacotherapy

Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy

Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants

European Heart Journal - Cardiovascular Pharmacotherapy

Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy

Sodium–glucose co-transporter 2 inhibitors in heart failure

European Heart Journal - Cardiovascular Pharmacotherapy

A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?

European Heart Journal - Cardiovascular Pharmacotherapy

Left ventricular thrombosis: new perspectives on an old problem

European Heart Journal - Cardiovascular Pharmacotherapy

A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

European Heart Journal - Cardiovascular Pharmacotherapy

Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk—an inverse probability of treatment weighted study on 54 872 patients

European Heart Journal - Cardiovascular Pharmacotherapy

The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management

European Heart Journal - Cardiovascular Pharmacotherapy

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

European Heart Journal - Cardiovascular Pharmacotherapy

Antihypertensive drugs in COVID-19 infection

European Heart Journal - Cardiovascular Pharmacotherapy

Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs

European Heart Journal - Cardiovascular Pharmacotherapy

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease

European Heart Journal - Cardiovascular Pharmacotherapy

Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial

European Heart Journal - Cardiovascular Pharmacotherapy

Speculation is not evidence: antihypertensive therapy and COVID-19

European Heart Journal - Cardiovascular Pharmacotherapy

All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease

European Heart Journal - Cardiovascular Pharmacotherapy

Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

European Heart Journal - Cardiovascular Pharmacotherapy

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

European Heart Journal - Cardiovascular Pharmacotherapy

PCSK9 and inflammation: a review of experimental and clinical evidence

European Heart Journal - Cardiovascular Pharmacotherapy

Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy

European Heart Journal - Cardiovascular Pharmacotherapy

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system

European Heart Journal - Cardiovascular Pharmacotherapy

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study

European Heart Journal - Cardiovascular Pharmacotherapy

Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1

European Heart Journal - Cardiovascular Pharmacotherapy

Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

European Heart Journal - Cardiovascular Pharmacotherapy

Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study

European Heart Journal - Cardiovascular Pharmacotherapy

Is P2Y<sub>12</sub> inhibitor therapy associated with an increased risk of cancer?

European Heart Journal - Cardiovascular Pharmacotherapy

ESC Council on hypertension position document on the management of hypertensive emergencies

European Heart Journal - Cardiovascular Pharmacotherapy

Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review

European Heart Journal - Cardiovascular Pharmacotherapy

A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation

European Heart Journal - Cardiovascular Pharmacotherapy

Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction

European Heart Journal - Cardiovascular Pharmacotherapy

Gender differences in the effects of cardiovascular drugs

European Heart Journal - Cardiovascular Pharmacotherapy